verapamil has been researched along with Tauopathies in 2 studies
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.
verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.
2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.
Tauopathies: Neurodegenerative disorders involving deposition of abnormal tau protein isoforms (TAU PROTEINS) in neurons and glial cells in the brain. Pathological aggregations of tau proteins are associated with mutation of the tau gene on chromosome 17 in patients with ALZHEIMER DISEASE; DEMENTIA; PARKINSONIAN DISORDERS; progressive supranuclear palsy (SUPRANUCLEAR PALSY, PROGRESSIVE); and corticobasal degeneration.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This led to the identification of selected triazolopyrimidines and phenylpyrimidines that are orally bioavailable and brain-penetrant without disruption of Pgp function." | 1.40 | Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies. ( Ballatore, C; Brunden, KR; Cornec, AS; Gay, B; Hoye, AT; Hyde, E; James, MJ; Lee, VM; Lou, K; Smith, AB; Trojanowski, JQ; Yao, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lou, K | 1 |
| Yao, Y | 1 |
| Hoye, AT | 1 |
| James, MJ | 1 |
| Cornec, AS | 1 |
| Hyde, E | 1 |
| Gay, B | 1 |
| Lee, VM | 1 |
| Trojanowski, JQ | 1 |
| Smith, AB | 1 |
| Brunden, KR | 1 |
| Ballatore, C | 1 |
| Di Pietro, O | 1 |
| Pérez-Areales, FJ | 1 |
| Juárez-Jiménez, J | 1 |
| Espargaró, A | 1 |
| Clos, MV | 1 |
| Pérez, B | 1 |
| Lavilla, R | 1 |
| Sabaté, R | 1 |
| Luque, FJ | 1 |
| Muñoz-Torrero, D | 1 |
2 other studies available for verapamil and Tauopathies
| Article | Year |
|---|---|
Brain-penetrant, orally bioavailable microtubule-stabilizing small molecules are potential candidate therapeutics for Alzheimer's disease and related tauopathies.
Topics: Administration, Oral; Alzheimer Disease; Animals; Biological Availability; Brain; Cell Line; Humans; | 2014 |
Tetrahydrobenzo[h][1,6]naphthyridine-6-chlorotacrine hybrids as a new family of anti-Alzheimer agents targeting β-amyloid, tau, and cholinesterase pathologies.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Dose-Response | 2014 |